#United States #Bexion Pharmaceuticals #Charles Scheper #Great Living Cincinnatian #Covington

Significant Honor for a Distinguished Leader

On December 6, 2024, Bexion Pharmaceuticals, a clinical-stage biopharmaceutical entity focused on developing advanced therapies for solid tumors, announced a remarkable achievement for Charles R. Scheper, its Chairman of the Board. He has been honored as a Great Living Cincinnatian by The Cincinnati Regional Chamber, an accolade celebrated throughout the community for its recognition of exceptional service and leadership.

According to the Cincinnati Regional Chamber, this prestigious distinction is awarded to individuals who have significantly impacted the community through their business acumen, civic engagement, leadership, and unique achievements. It highlights not only a person's professional accomplishments but also their commitment to addressing the needs of others, rewarding those who inspire and facilitate positive change.

Chuck Scheper, also known as Charles R. Scheper, has played a crucial role in the operations at Bexion Pharmaceuticals since he joined the board in 2010. Before this, he was the Chief Operating Officer at Great American Financial Resources, a major entity in life and annuity financial services. With decades of experience, including leadership positions at Manhattan National Life Insurance Company and Pioneer Financial Services, Scheper brings a wealth of knowledge to the biopharmaceutical field.

A cancer survivor himself, Scheper's journey has driven him to engage deeply with cancer-related causes. Notably, he has served as the National Board Chairperson for the Cancer Support Community, illustrating his dedication to helping others facing similar challenges. Presently, he also chairs the Catalytic Development Funding Corp of Northern Kentucky and the Covington Economic Development Authority, further contributing to the economic growth and welfare of the community.

In a heartfelt statement, Jim Beach, CEO of Bexion Pharmaceuticals, expressed immense pride in Scheper’s achievement, emphasizing how this recognition exemplifies his leadership qualities and profound influence on the community. “Chuck embodies the values we strive for at Bexion,” Beach remarked, highlighting the inspiration Scheper provides to those around him.

Bexion Pharmaceuticals is making significant strides in the biopharmaceutical landscape, particularly with its lead drug candidate, BXQ-350, a groundbreaking biologic therapy targeting solid tumors and chemotherapy-induced peripheral neuropathy. This product is positioned to address a high medical need within oncology, and the company has engaged in multiple Phase 1 clinical trials demonstrating the drug’s safety and efficacy.

As the company progresses, Scheper’s visionary leadership is pivotal in navigating complex clinical pathways and forging initiatives that promise to enhance patient lives. Bexion’s innovative approach and dedication to expanding treatment opportunities position it as a leader in the biopharmaceutical space, making the honor bestowed upon Scheper not only timely but also reflective of his contributions to advancing medical treatments and community wellbeing.

The Great Living Cincinnatian award ceremony is set for 2025, where Scheper will be among other esteemed honorees celebrated for their impactful work. As the Cincinnati Regional Chamber aims to cultivate a prosperous and inclusive region, individuals like Scheper play a vital role in achieving this vision.

For those interested in learning more about the upcoming awards and Scheper’s contributions, further information can be accessed through the Cincinnati Regional Chamber’s official channels.

About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical-stage company dedicated to developing novel biologic therapies targeting solid tumor cancers and chemotherapy-related side effects. With robust clinical data and a clear vision for expanding its therapeutic portfolio, Bexion continues to innovate within the biopharmaceutical sector.

Contact
For media inquiries, reach out to Joyce LaViscount at Bexion Pharmaceuticals at 859-446-7386.